Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

Starting April 1, CVS Health Corp will no longer offer AbbVie Inc’s Humira to most of the millions of patients in its commercial prescription plans. Instead, they’ll be directed to cheaper ...

According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy provider agreement for commercial customers because of an “unsustainable” ...

AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's ...

These strong results demonstrate AbbVie's resilience in navigating the transition away from its former flagship product, as Humira sales decreased by 49% to $1.68 billion in the fourth quarter.

Humira is the company's blockbuster immunology drug, which has faced competition from biosimilars since 2023. North Chicago, Ill.-based AbbVie (ABBV) had a loss per share of 2 cents, due to an ...

AbbVie (NYSE: ABBV) is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira’s patent cliff are ...

The demand for those two treatments offset continuing falling sales of its former blockbuster medicine, Humira. AbbVie raised its long-term outlook for Skyrizi and Rinvoq revenue. AbbVie (ABBV ...

AbbVie Inc.’s stock rose 7.7% Friday to lead ... delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase ...

“We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity,” said Robert A.

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset.